REVANCE.COM: Keyword Density Checker

Total words: 2665 | 2-word phrases: 677 | 3-word phrases: 778 | 4-word phrases: 834

PAGE INFO

Title	Try to keep the title under 60 characters (14 characters) Home - Revance
Description	Try to keep the meta description between 50 - 160 characters (159 characters) Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, as well as financial technology services for aesthetic practices.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (60 characters) The Only Long-Lasting, Peptide-Powered Frown Line Treatment.

#	Keyword	Frequency	Density
1	daxibotulinumtoxina for injection	8	1.03%
2	products and pipeline	5	0.64%
3	distant spread of	4	0.51%
4	spread of toxin	4	0.51%
5	botulinum toxin products	4	0.51%
6	the effect of	4	0.51%
7	for injection is	4	0.51%
8	of toxin effect	4	0.51%
9	may 9 2024	3	0.39%
10	the treatment of	3	0.39%
11	important safety information	3	0.39%
12	investors investor relations	3	0.39%
13	toxin effect the	3	0.39%
14	careers opportunities culture	3	0.39%
15	opportunities culture benefits	3	0.39%
16	grants investigator sponsored	3	0.39%
17	educational grants investigator	3	0.39%
18	sustainability medical educational	3	0.39%
19	for the treatment	3	0.39%
20	appearance of moderate	2	0.26%
21	the appearance of	2	0.26%
22	in the appearance	2	0.26%
23	improvement in the	2	0.26%
24	headache 6 eyelid	2	0.26%
25	indicated for the	2	0.26%
26	agent indicated for	2	0.26%
27	of moderate to	2	0.26%
28	moderate to severe	2	0.26%
29	observed adverse reactions	2	0.26%
30	associated with corrugator	2	0.26%

#	Keyword	Frequency	Density
1	daxibotulinumtoxina for injection is	4	0.48%
2	spread of toxin effect	4	0.48%
3	distant spread of toxin	4	0.48%
4	for the treatment of	3	0.36%
5	of toxin effect the	3	0.36%
6	not be exceeded patients	2	0.24%
7	appearance of moderate to	2	0.24%
8	the appearance of moderate	2	0.24%
9	in the appearance of	2	0.24%
10	improvement in the appearance	2	0.24%
11	should not be exceeded	2	0.24%
12	toxin products recommended dose	2	0.24%
13	be exceeded patients should	2	0.24%
14	seek immediate medical attention	2	0.24%
15	administration should not be	2	0.24%
16	agent indicated for the	2	0.24%
17	blocking agent indicated for	2	0.24%
18	neuromuscular blocking agent indicated	2	0.24%
19	and neuromuscular blocking agent	2	0.24%
20	of moderate to severe	2	0.24%
21	products recommended dose and	2	0.24%
22	of administration should not	2	0.24%
23	of other botulinum toxin	2	0.24%
24	effect the effects of	2	0.24%
25	toxin effect the effects	2	0.24%
26	warning distant spread of	2	0.24%
27	are not interchangeable with	2	0.24%
28	not interchangeable with other	2	0.24%
29	preparations of other botulinum	2	0.24%
30	other botulinum toxin products	2	0.24%
31	frequency of administration should	2	0.24%
32	botulinum toxin products recommended	2	0.24%
33	corrugator andor procerus muscle	2	0.24%
34	with corrugator andor procerus	2	0.24%
35	associated with corrugator andor	2	0.24%
36	use in children or	2	0.24%
37	first quarter 2024 financial	2	0.24%
38	immediate medical attention if	2	0.24%
39	inhibitor and neuromuscular blocking	2	0.24%
40	attention if respiratory speech	2	0.24%

#	URL	Whois	Check
1	https://hcp.daxxify.com/	Whois	daxxify.com
2	https://rha.revanceaesthetics.com/	Whois	revanceaesthetics.com
3	https://hcp.daxxify.com/	Whois	daxxify.com
4	http://www.fda.gov/medwatch.	Whois	fda.gov